Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

13.65
+0.18001.34%
Volume:204.77K
Turnover:2.80M
Market Cap:2.21B
PE:619.38
High:13.82
Open:13.48
Low:13.47
Close:13.47
52wk High:26.54
52wk Low:10.21
Shares:162.00M
Float Shares:70.89M
Volume Ratio:0.62
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0220
EPS(LYR):0.0444
ROE:1.46%
ROA:0.65%
PB:9.17
PE(LYR):307.46

Loading ...

BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 13

Vertex Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Jul 11

Crinetics Pharmaceuticals Announces Merger Agreement With Vertex

TIPRANKS
·
Jul 11

Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained

TIPRANKS
·
Jul 10

RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570

MT Newswires Live
·
Jul 10

Vertex Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 09

Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 08

Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580

MT Newswires Live
·
Jul 08

Crinetics downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
Jul 08

Vertex (VERX) Could Be 28% Undervalued As TD Cowen Backs Its Profit Plan

Simply Wall St.
·
Jul 08

Press Release: Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Dow Jones
·
Jul 08

Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says

MT Newswires Live
·
Jul 08

Crinetics downgraded to Market Perform from Outperform at Citizens

TIPRANKS
·
Jul 08

Wedbush sees BioCryst, Ascendis as potential next targets after Crinetics deal

TIPRANKS
·
Jul 07

Cantor Sees 'clear Strategic Rationale' Behind Vertex's Buy of Crinetics

Dow Jones
·
Jul 07

Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets

Benzinga
·
Jul 07

This Biotech Stock is Soaring 99% After Vertex Agrees to Takeover Deal

Dow Jones
·
Jul 07

Citi Remains a Buy on Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Jul 07

Vertex Pharmaceuticals is Maintained at Underperform by Baird

Dow Jones
·
Jul 07

Baird Adjusts Price Target on Vertex Pharmaceuticals to $350 From $330

MT Newswires Live
·
Jul 07